EZH2 and breast carcinoma: The genetic deletion of EZH2 reportedly resulted in the down-regulation of cyclin D1 in breast cancer and caused the up-regulation of p21 in ovarian cancer, triggering cell-cycle arrest at the G1/S phase (32).